INTRODUCTION:

The term nano originates from the Latin word meaning “dwarf,” reflecting the extremely small scale at which nanotechnology operates. Nanotechnology represents a highly interdisciplinary field that integrates principles from chemistry, physics, biology, and material science to design, synthesize, and characterize materials and systems at the nanometer scale, typically between 1 and 100nm. At this dimension, materials exhibit unique physicochemical properties due to their increased surface area and altered atomic interactions, enabling functionalities not observed at the bulk level.

Rather than being a single distinct discipline, nanotechnology serves as a convergence platform for multiple scientific areas, allowing researchers to develop innovative tools and technologies. Scientists worldwide are exploring its potential to address challenges in energy, environment, defense, and human health. These efforts envision a future where nanoscale materials contribute to sustainable energy production, environmental protection, and advanced medical interventions capable of early disease detection and effective treatment of conditions such as cancer, cardiovascular disorders, and diabetes. Although several scientific hurdles still remain, nanotechnology has facilitated significant breakthroughs and opened new avenues for molecular-level investigation and technological advancement.

The rapid growth of nanotechnology applications across numerous sectors has spurred increased interest in optimizing system performance in engineering, electronics, computing, and biomedical sciences. In the pharmaceutical field, nanotechnology has emerged as a transformative approach for enhancing drug delivery and therapeutic outcomes. A wide range of nanocarrier systems—such as liposomes, dendrimers, polymeric nanoparticles, solid lipid nanoparticles, and metallic nanostructures—have shown the ability to overcome limitations associated with conventional drug formulations. These nanoscale systems enable site-specific drug delivery, improved solubility, controlled and sustained release, and enhanced bioavailability. They can also traverse biological barriers, reduce off-target toxicity, and increase patient compliance by allowing reduced dosing frequency.

This review summarizes recent developments in nanotechnology-based drug delivery platforms, with particular attention to their targeting strategies and therapeutic roles in cancer, neurological disorders, and infectious diseases. Additionally, it addresses ongoing challenges, safety considerations, and regulatory frameworks that influence the successful clinical translation of nanomedicines.

Nanotechnology in Targeted Drug Delivery:

Targeted drug delivery system is defined as system in which drug is transported to the site of action. This system also prevents the unnecessary interactions with other health tissues. It helps in reducing the drug dosage and improving the uniformity of drug effect. It takes place in cytosol and cell membrane. Using large sized materials for drug delivery presents multiple difficulties such as low stability within the body, limited solubility and absorption, poor bioavailability and lack of precision in targeting specific sites.

Moreover, these materials can cause unwanted side effects. Hence, the development of advanced drug delivery system capable of directing drugs to particular regions of the body offers a promising solution to overcome these challenges.

Nanotechnology focuses on designing nanoscale materials made from polymers, lipids, or metals that can serve as efficient carriers for therapeutic agents. These nanoparticles (NPs) are capable of enhancing drug delivery by improving the biological stability, bioavailability, and controlled accumulation of drugs in the desired tissues. Colloidal-based nanocarriers can deliver drugs directly to targeted sites, thereby increasing treatment efficiency, minimizing toxicity, and reducing side effects. They also protect drugs from premature degradation and ensure spatial and temporal control over drug release at the specific site of a disease.

Initially, nanocarriers were primarily designed based on passive targeting mechanisms, where drugs accumulate in diseased tissues through the Enhanced Permeability and Retention (EPR) effect. However, active targeting approaches have now been developed, where nanoparticles are functionalized with specific ligands that recognize and bind to target cell receptors. This strategy enhances site-specific delivery and overall therapeutic performance. Nanotechnology therefore offers immense potential for innovation in both drug formulations and delivery systems.

Achieving a therapeutic outcome that effectively treats tumors, inflammatory, or immune-related diseases requires a system that delivers drugs precisely to the desired site. Consequently, ongoing research in nanotechnology seeks to explore novel materials, delivery agents, and modeling techniques to predict and optimize nanoparticle behavior within the body. Studies have also examined magnetic nanoparticles, lipid-based carriers, and biodegradable polymeric systems for targeted delivery of various drugs, particularly anticancer and antiviral agents.

Overall, nanotechnology-based delivery platforms, such as liposomes, polymeric nanoparticles, and hybrid nano systems represent a major advancement in overcoming the limitations of traditional therapies. By enhancing bioavailability, reducing systemic toxicity, and ensuring controlled release, they have significantly improved the efficiency and safety of drug delivery systems.

Nanotechnology in Controlled Drug Delivery System:

Nanoscience and nanotechnology have greatly influenced the advancement of controlled drug delivery (CDD) systems by providing innovative scientific tools for precise manipulation and observation at the molecular level. These technologies have enhanced our understanding of diseases and drug actions, paving the way for the development of safer and more efficient therapeutic methods. With the ability to design nanomedicines that specifically target diseased cells or organelles, drug release can now be localized and optimized according to the body’s therapeutic needs in real time.

The emergence of nanotechnology in pharmaceuticals has led to improved characterization techniques and more efficient drug formulation processes. Modern methods such as combinatorial chemistry and high-throughput screening have accelerated the discovery of new biomaterials and bioactive agents. Furthermore, nanomedicines are designed to enhance the safety, efficacy, and bioavailability of therapeutic compounds, addressing long-standing challenges in conventional drug delivery.

Successful integration of nanomedicine into clinical applications requires interdisciplinary collaboration, focusing on both technological innovation and regulatory compliance. The use of nanocarriers-like liposomes, polymeric nanoparticles, and micelles, has shown promising results for targeted therapy, sustained release, and reduction of side effects. However, ongoing challenges such as large-scale production, long-term safety, and ethical concerns remain to be resolved.

In addition, genomic and molecular biology tools have improved the identification of specific cellular targets and clarified the mechanisms of drug action. Understanding cellular transport systems, such as ATP-binding cassette (ABC) transporters, has further contributed to overcoming drug resistance and improving therapeutic outcomes. Recent progress in bioengineering and nanocarrier systems continues to drive innovation in targeted and controlled drug delivery, moving toward more precise and personalized treatments.

Advantages:

· The small size of nanocarrier in nanotechnology improve solubility and permeability of poorly water-soluble drugs. The small size of particles allows for site specific targeted, reducing systemic side effects and improving therapeutic activity.

· Nanotechnology ensures prolonged therapeutic activity by designing of drug delivery systems capable of providing controlled or sustained drug release.

· Nanotechnology has enhanced diagnostic and imaging capabilities.

· Nanotechnology allows the development of diverse formulations and is versatile in formulation design.

· It improves pharmacokinetic and pharmacodynamic profiles resulting in improved bio efficacy.

· It improves stability of formulations by enhancing the physical and chemical stability of drugs.

· It requires lower doses and fewer administrations which reduces long term treatment cost.

Disadvantages:

· Many nanoparticles—particularly metallic and inorganic ones such as silver, zinc oxide, and carbon nanotubes—can cause cellular and genetic toxicity, as well as oxidative damage in biological systems. Due to their nanoscale size, they can easily cross biological membranes, accumulate within various organs, and potentially induce long-term adverse effects that are not yet fully understood.

· The production of nanomaterials typically demands sophisticated equipment and intricate manufacturing methods, which increases costs and limits large-scale application, especially in developing countries. Additionally, unsafe disposal or unintentional release of these materials can pollute soil and water, resulting in their accumulation in living organisms and causing disturbances to ecological balance.

· The synthesis of nanomaterials generally involves the use of specialized equipment and intricate techniques, which makes mass production costly and less feasible in developing countries.

· Improper disposal or accidental leakage of nanomaterials can pollute soil and water, resulting in their buildup within plants, animals, and humans, which may ultimately disturb ecological balance.

· The long-term effects of continuous exposure to nanomaterials on human health and the environment are still uncertain, highlighting the need for comprehensive toxicological and epidemiological studies.

· Regulatory agencies closely evaluate nano formulated drugs because of issues related to their pharmacokinetics, stability, and possible toxicity, which often results in extended approval processes.

Preparation Methods Used in Nanotechnology:

Bottom-Up Technology:

1. Precipitation method: Over the last ten years, the precipitation method has been widely employed to produce submicron particles, especially for drugs with poor solubility. In this process, the drug is first dissolved in a suitable solvent and then mixed with a miscible antisolvent, usually water, in the presence of surfactants. Rapid addition of the drug solution to the antisolvent causes supersaturation, leading to the creation of fine crystalline or amorphous drug particles. The process occurs in two main steps: nucleation and crystal growth. Achieving a high nucleation rate and a low crystal growth rate is crucial for obtaining a stable dispersion with minimal particle size. Temperature plays a significant role in these steps—the best temperature for nucleation is often lower than that for crystal growth, enabling control through temperature adjustment. This technique is straightforward, inexpensive, and easily scalable for industrial use. However, the use of surfactants is required to manage crystal growth, and the drug must be soluble in at least one of the solvents used.

2. Super Critical Fluid Process: Supercritical fluid (SCF) techniques, when integrated with solubilization and nanosizing methods, help achieve further particle size reduction. SCFs are dense, non-condensable fluids that exist at temperatures and pressures above their critical temperature (Tc) and critical pressure (Tp). This approach enables the micronization of drug particles down to the submicron range. Recent developments in SCF technology have made it possible to produce nanoparticle suspensions with sizes between 5 and 2000 nm. However, the limited solubility of surfactants and poorly water-soluble drugs in supercritical CO₂, along with the need for high operating pressures, restricts the broader use of this technique in the pharmaceutical industry.

Additionally, newer bottom-up approaches—such as liquid antisolvent precipitation, acid-base-assisted precipitation, and emulsion polymerization—provide improved control over particle size and distribution.

3. Liquid emulsion technique: The Liquid emulsion technique is a widely used method for preparing nanoparticles, microspheres, and nanocarriers in pharmaceutical formulations. It is based on forming an emulsion a mixture of two immiscible liquids usually oil and water followed by solidification of the dispersed phase. The method involves emulsifying a drug containing polymer solution in an aqueous phase with the help of surfactants or stabilizers. When the solvent of the dispersed phase evaporates or diffuses, nanoparticles are formed.

Top-Down Technology:

1. Media Milling: Nanosuspensions are commonly prepared using high-shear media or pearl milling techniques. The milling system typically includes a milling chamber, shaft, and recirculation unit. In this process, an aqueous drug suspension is introduced into the mill containing small grinding balls or pearls. As these media rotate at high shear rates under controlled temperature conditions, they collide with the drug particles and the chamber walls, generating intense friction and impact forces that effectively reduce particle size. The grinding media are generally composed of materials such as ceramic-sintered aluminum oxide, zirconium oxide, or highly cross-linked polystyrene resin, all known for their strong abrasion resistance. Planetary ball mills (e.g., PM100 and PM200, Retsch GmbH & Co., KG, Haan, Germany) are examples of equipment capable of achieving particle sizes below 0.1 μm. For instance, a Zn–Insulin nanosuspension with an average particle size of 150 nm has been successfully produced using the wet milling approach. However, this technique has some limitations, including potential contamination from the erosion of milling media, thermal degradation of heat-sensitive drugs due to process-generated heat, and the formation of relatively large particles (≥5 μm) within the final product.

2. High-Pressure Homogenization: High-pressure homogenization is a widely adopted top-down method for generating nanosuspensions from coarse drug particles. During this process, a drug dispersion is forced at extremely high pressure through a narrow homogenization valve. Inside the valve, the sudden drop in pressure creates intense turbulence and cavitation bubbles. When these bubbles collapse, powerful shear and impact forces fracture the drug particles into the nanometer range. Multiple homogenization cycles are typically required to achieve uniform particle size distribution, with parameters such as pressure intensity, formulation viscosity, and drug hardness influencing efficiency. The technique is suitable for both dilute and concentrated systems, scalable to industrial production, and compatible with sterile manufacturing environments.

3.Co-Grinding: Co-grinding, also referred to as dry co-grinding or mechanochemical milling, is a top-down approach employed to achieve nanoscale particle reduction. In this technique, the active pharmaceutical ingredient (API) is simultaneously ground with one or more excipients—such as polymers, stabilizers, or surfactants—to decrease particle size, modify surface properties, and enhance dissolution performance. The mixture of drug and excipient is introduced into a milling chamber containing grinding media, where it is exposed to mechanical forces including shear, impact, and attrition. These forces not only reduce the particle size of the drug but also promote uniform mixing with the excipients. The incorporated excipients serve several critical functions: they prevent aggregation of nanoparticles, aid in disrupting the drug’s crystalline matrix (leading in some cases to partial amorphization), and modify surface characteristics—such as increasing hydrophilicity—which collectively improve wettability and dissolution behavior.

CHARACTERIZATION TECHNIQUES:

In- Vitro Evaluations:

1. Organoleptic Properties: Sensory changes such as alterations in taste, odor, or color often serve as early indicators of chemical instability or degradation processes occurring within the formulation. These changes may result from oxidation, hydrolysis, or interactions between the active pharmaceutical ingredient (API) and excipients. Therefore, continuous monitoring of these physical and sensory attributes is essential during formulation development and stability testing to ensure product quality, efficacy, and patient acceptability.

2. Particle Size Distribution: Particle size plays a vital role in determining key physicochemical properties such as dissolution rate, saturation solubility, and physical stability of a formulation. Various analytical techniques are employed to assess particle size distribution, including the Coulter Counter Multisizer, laser diffraction (LD), and photon correlation spectroscopy (PCS). PCS is capable of measuring particles within the range of 3 nm to 3 µm, whereas LD covers a broader range of approximately 0.05–80 µm. Unlike LD, which provides a relative size distribution, the Coulter Counter Multisizer offers an absolute particle count. For intravenous (IV) formulations, it is essential to maintain particle sizes below 5 µm to prevent potential complications such as capillary blockage or embolism, since the smallest capillaries measure around 5–6 µm in diameter.

3. Dissolution rate and saturation solubility: Nanosuspensions offer a distinct advantage over conventional formulations by enhancing both saturation solubility and dissolution rate. Evaluating these properties in various physiological media is essential to fully understand the formulation’s in vitro performance. As reported by Böhm et al., reducing particle size to the nanoscale can significantly increase dissolution pressure and rate, demonstrating that smaller particles dissolve more rapidly.

4. Crystal morphology: Crystal morphology can be evaluated using techniques such as X-ray diffraction (XRD) in combination with differential thermal analysis (DTA) or differential scanning calorimetry (DSC) to investigate the effects of high-pressure homogenization on a drug’s crystalline structure. In nanosuspensions, this process may induce changes in crystallinity, leading to the formation of amorphous regions or alternative polymorphic forms.

5. Zeta potential: Zeta potential is commonly used to assess the stability of colloidal suspensions. For suspensions stabilized purely by electrostatic repulsion, a zeta potential of at least 30 mV is generally required to ensure stability. However, when both electrostatic and steric stabilization mechanisms are present, a lower zeta potential of around 20 mV is considered sufficient to maintain stability.

In Vivo Evaluations:

1. Safety and Toxicity: Despite their advantages, nanoparticles may pose unique toxicological challenges. In vivo toxicity assessments include hematological and biochemical analysis, as well as histopathological examinations of major organs. These studies evaluate potential systemic toxicity, immune responses, and organ-specific damage. The safety profile often depends on the nanoparticle’s material, size, surface chemistry, and dose.

2. Therapeutic Efficacy: In vivo performance studies also include the evaluation of pharmacodynamic responses in relevant disease models. Nanoparticles have demonstrated improved efficacy in tumor regression, infection control, and sustained drug release compared to conventional formulations. Controlled release, targeted delivery, and reduced systemic exposure contribute to enhanced therapeutic outcomes.

3. Imaging Techniques: Non-invasive imaging allows dynamic tracking of nanoparticles in living organisms:

· Fluorescence Imaging: Real-time tracking using fluorescent probes; limited by tissue penetration.

· Bioluminescence Imaging: High sensitivity detection of nanoparticles via luminescent reporters.

· Magnetic Resonance Imaging (MRI): High-resolution, non-ionizing imaging of nanoparticle localization.

· PET/CT: Combines functional and anatomical imaging using radiolabeled nanoparticles for quantitative biodistribution.

4. Histological Analysis: Histology provides tissue-level insights into nanoparticle effects:

· Hematoxylin & Eosin (H&E) Staining: Evaluates tissue morphology and pathological changes.

· Immunohistochemistry (IHC): Detects biomarkers for apoptosis, inflammation, or cellular uptake.

5. Blood and Serum Analysis: Assesses systemic toxicity and organ function:

· Liver and Kidney Function Tests: ALT, AST, creatinine, and BUN as indicators of organ health.

· Complete Blood Count (CBC): Monitors hematological changes or immune activation

Applications:

1. Nanomedicine: Nanotechnology has revolutionized healthcare by enabling targeted drug delivery, advanced diagnostics, and regenerative therapies. Nanoscale carriers, including liposomes, polymeric nanoparticles, dendrimers, and metallic nanoparticles, enhance drug bioavailability and specificity while minimizing systemic toxicity. For instance, studies have demonstrated that liposomal doxorubicin preferentially accumulates in tumor tissues, reducing cardiotoxic effects. Furthermore, nanoparticles serve as contrast agents in imaging techniques such as MRI, PET, and CT, thereby improving early disease detection.

2. Diagnostics and Imaging: The integration of nanomaterials into diagnostic platforms has significantly improved the sensitivity and precision of biomarker detection. Materials such as quantum dots, gold nanoparticles, and magnetic nanoparticles are widely used in biosensing and molecular imaging applications, facilitating the detection of low-abundance biological targets. Gold nanoparticles, for example, can be functionalized with antibodies to enable rapid, colorimetric detection of cancer biomarkers.

3. Electronics and Information Technology: In electronics, nanotechnology supports device miniaturization and enhanced performance. Carbon-based nanomaterials, including graphene and carbon nanotubes, exhibit exceptional electrical conductivity and mechanical strength, enabling the development of faster, smaller, and more energy-efficient components such as transistors, memory devices, and sensors.

4. Food and Agriculture: Nanotechnology offers innovative solutions in agriculture and food safety. Nano formulated fertilizers and pesticides enable controlled release, reducing environmental impact while improving efficacy. Research indicates that nano-encapsulated pesticides can minimize leaching and optimize targeted delivery to crops, enhancing productivity and sustainability.

5. Anticancer: Biomedical applications, particularly in cancer therapy, have driven significant interest in certain nanomaterials. Precious metals, notably gold (Au) and silver (Ag), as well as magnetic oxides such as magnetite (Fe₃O₄), have been extensively studied, alongside quantum dots and naturally derived nanoparticles (Bououdina et al., 2013). Additionally, the distinctive up conversion properties of up conversion nanoparticles (UCNPs) offer potential for activating photosensitive therapeutic agents, providing promising strategies for cancer treatment.

6. Application in food: The term nanofood refers to foods developed using nanotechnology techniques, tools, or engineered nanomaterials introduced at any stage of cultivation, production, processing, or packaging. The development of nanofood serves multiple purposes, including improving food safety, enhancing nutritional value and flavor, and reducing production and consumer costs. Moreover, nanofood offers additional benefits such as health-promoting additives, extended shelf life, and novel flavor profiles.

7. Applications of Nanoparticles in Gene Delivery: Gene delivery is a critical technique for efficiently introducing a target gene to achieve expression of its encoded protein in a suitable host or host cell. Traditionally, gene delivery systems have relied on viral vectors, including retroviruses and adenoviruses, as well as non-viral approaches such as nucleic acid electroporation and transfection. In recent years, nanoparticles have emerged as promising carriers for gene delivery, offering advantages such as enhanced cellular uptake, protection of nucleic acids from degradation, targeted delivery, and reduced immunogenicity.

8. Targeted Drug Delivery: The size of drug-loaded nanoparticles plays a crucial role in their absorption and overall therapeutic efficacy. Targeted delivery can be achieved by modulating the in vivo behavior of nanoparticles through modifications of their physicochemical properties, particularly the surface characteristics. Approaches such as the development of smart crystals or stealth nanocrystals with particle sizes below 100 nm enable precise targeting. Among these strategies, the formulation of nanosuspensions offers a cost-effective and straightforward method for achieving targeted delivery. Key surface properties—including hydrophobicity, surface charge, and the type or density of functional groups—significantly influence the biodistribution of nanoparticles. Notably, the potential of Tween 80-coated nanocrystals for brain-targeted delivery has been demonstrated; for instance, atovaquone nanocrystals coated with Tween 80 effectively eliminated parasites in the brain during toxoplasmosis treatment, highlighting the promise of surface-engineered nanoparticles for organ-specific therapy.

9. Environmental Applications: Nanotechnology offers several eco-friendly solutions for environmental management. Ion-based air purification systems enhance the removal of airborne pollutants, while advanced wastewater treatment technologies—such as nanobubbles and nanofiltration membranes, enable efficient elimination of heavy metals and other contaminants. Additionally, nano catalysts contribute to cleaner industrial processes by improving reaction efficiency and reducing the generation of harmful by-products.

10. Cardiovascular Diseases: Nanotechnology, as an interdisciplinary innovation, offers promising solutions to overcome these challenges. In the therapeutic domain, various nanocarriers such as liposomes, polymeric nanoparticles (e.g., PLGA), inorganic nanoparticles (AuNPs, MnO₂), natural nanoparticles (HDL, hyaluronic acid), and biomimetic platforms (such as cell-membrane–coated nanostructures) are being engineered for targeted delivery of drugs, peptides, proteins, and nucleic acids directly to pathological lesions.

11. Diabetes: Nanotechnology has significantly advanced diabetes research by enabling innovative strategies for both glucose monitoring and insulin administration. Recent developments highlight how nanoscale materials have improved the performance of glucose-sensing platforms. Metal nanoparticles, carbon-based nanostructures, and other nanomaterials enhance sensor sensitivity, accelerate response times, and support the creation of continuous in vivo glucose monitoring systems. Beyond diagnostics, nanotechnology is also central to emerging “closed-loop” insulin delivery systems, in which insulin release is automatically modulated according to real-time blood glucose levels.

Recent Advances in Nanotechnology:

Nanotechnology is a rapidly evolving field characterized by continuous innovations and breakthroughs across diverse scientific and industrial domains. While ongoing developments occur at a fast pace, several notable recent trends can be highlighted:

Nanomedicine: Significant progress has been made in the development of targeted drug delivery systems, particularly for cancer therapy, enabling more precise and effective treatments. In addition, nanoscale imaging agents are being engineered for earlier and more accurate disease diagnosis.

Nanoelectronics: Efforts continue to push the limits of Moore’s Law, with the design of nanoscale transistors, memory devices, and novel 2D materials such as graphene for electronic components and interconnects.

Quantum Nanotechnology: Advances in quantum computing and communication rely on nanoscale quantum bits (qubits), while quantum sensors and detectors are being developed for applications in metrology, cryptography, and precision measurement.

Energy Applications: Nanomaterials are increasingly applied to energy technologies, including high-efficiency solar cells (notably perovskite-based), high-capacity batteries, supercapacitors, and thermoelectric devices aimed at improving energy conversion and storage.

Environmental Remediation: Nano catalysts and nanomaterial-based filtration systems are being explored for pollution control, wastewater treatment, and water purification, offering enhanced efficiency and sustainability.

Materials Science: Novel nanocomposites with improved strength, conductivity, and other functional properties are being developed. Advances in nanoscale fabrication techniques also support the manufacturing of miniaturized devices and components.

Food and Agriculture: Nanotechnology is being applied in food packaging to extend shelf life and reduce waste. Nanoscale delivery systems for precision agriculture, including targeted nutrient and pesticide delivery, are also gaining attention.

Nanorobotics: Progress is being made in engineering nanoscale robots capable of performing tasks at the molecular level, with potential applications in medicine, manufacturing, and environmental monitoring.

Ethics, Safety, and Responsible Research: Increased focus is being placed on ethical considerations, safety protocols, and responsible research practices to ensure the sustainable and safe development of nanotechnology.

Advanced Imaging Techniques: Cutting-edge methods such as cryo-electron microscopy are enabling high-resolution visualization of nanoscale structures and dynamic processes.

Space and Clean Energy Applications: Nanotechnology is being explored in spacecraft materials, propulsion systems, sensors for space missions, and in technologies that enhance clean energy production and storage.

Future Prospects of Nanotechnology in Drug Delivery:

Nanotechnology has revolutionized pharmaceutical sciences by offering innovative solutions to longstanding challenges such as poor solubility, low bioavailability, and limited stability of therapeutic agents. Among various nanotechnology-based approaches, nanosuspensions have emerged as a promising platform for enhancing the delivery of hydrophobic drugs that are poorly soluble in both aqueous and organic media.

Production techniques like media milling and high-pressure homogenization have enabled scalable and reproducible manufacturing of nanosuspensions, facilitating their integration with traditional dosage forms such as tablets, capsules, pellets, and parenteral formulations. This versatility allows for tailored drug delivery while maintaining patient compliance, making nanosuspensions a valuable tool for both oral and non-oral applications.

The future of nanotechnology lies in the development of multifunctional nano systems capable of targeted, controlled, and sustained drug release. By modifying surface characteristics, particle size, and composition, nanosuspensions can improve tissue penetration, enhance cellular uptake, and reduce systemic toxicity. Moreover, stimuli-responsive and biomimetic nanoparticles offer the potential for precision medicine, enabling site-specific drug release in response to physiological triggers.

Beyond oral delivery, nanosuspensions are increasingly explored for ocular, pulmonary, transdermal, and intravenous routes, expanding the therapeutic scope of poorly soluble drugs. Additionally, combination therapies incorporating multiple drugs within a single nano system can improve treatment efficacy and patient adherence. Integration with emerging technologies such as 3D printing, personalized medicine, and advanced imaging further enhances the potential of nanosuspensions, enabling patient-specific dosage forms and real-time monitoring of drug distribution.

With the evolution of regulatory frameworks and advances in scalable production methods, nanotechnology-based therapeutics are poised for significant commercial growth. Nanosuspensions, in particular, represent a renaissance in formulation technology, offering practical solutions to challenges that have limited drug delivery for decades.

In conclusion, nanotechnology promises to reshape drug delivery by providing versatile, efficient, and patient-centric therapeutic strategies. Continued innovation in nanosuspension development and its integration with modern pharmaceutical technologies will ensure its pivotal role in future therapeutics, ultimately improving drug efficacy, safety, and patient outcomes.

CONCLUSION:

Nanotechnology has emerged as a transformative force in modern pharmaceutics, offering solutions to long-standing challenges in drug delivery, bioavailability, and therapeutic precision. Through nanosized carriers such as liposomes, polymeric nanoparticles, dendrimers, solid-lipid nanoparticles, and nanosuspensions, it is now possible to achieve targeted, controlled, and sustained drug release while minimizing systemic toxicity. These nano-enabled systems have shown significant potential in treating complex diseases such as cancer, neurological disorders, cardiovascular diseases, and diabetes by enabling site-specific delivery, improved cellular uptake, and enhanced diagnostic accuracy.

Recent advancements, including stimuli-responsive platforms, biomimetic nanocarriers, multifunctional hybrid systems, and integration with personalized medicine—highlight the rapid evolution of nano-therapeutics. However, several barriers remain, including scalability issues, long-term safety concerns, regulatory complexity, and the need for standardized characterization methods. Addressing these limitations through interdisciplinary research, robust toxicological evaluation, and harmonized regulatory frameworks will be crucial for translating nanotechnology-based innovations into widespread clinical applications.

Overall, nanotechnology represents a pivotal step toward next-generation therapeutics, providing opportunities for more effective, safer, and patient-centered drug delivery systems. Continued innovation in formulation engineering and nanoscale biomaterials will ensure that nanomedicine continues to redefine the future of pharmaceutical sciences.

REFERENCE:

1. G. A. Mansoori, Principles of Nanotechnology: Molecular-Based Study of Condensed Matter in Small Systems. Singapore: World Scientific, 2011.

2. C. Binns, Introduction to Nanoscience and Nanotechnology. Hoboken, NJ: Wiley, 2021.

3. M. C. Roco. The emergence and policy implications of converging new technologies. J. Nanopart. Res. 2005; 7(2–30: 129–143.

4. S. Mitragotri et al. Engineering of nanoparticles for targeted drug delivery. Nat. Rev. Drug Discov. 2022; 21(6): 424–448.

5. V. Torchilin. Multifunctional nanocarriers. Nat. Rev. Drug Discov. 2014; 13: 813–827.

6. R. Duncan and R. Gaspar. Nanomedicine—lessons learned. Adv. Drug Deliv. Rev. 2010; 62: 188–191.

7. M. E. Davis et al. Nanoparticle therapeutics: an emerging treatment modality. Nanomedicine. 2007; 2(6): 789–803.

8. S. Svenson. Dendrimers as versatile platform in drug delivery. Adv. Drug Deliv. Rev. 2005; 57: 2106–2129.

9. A. Akbarzadeh et al. Liposome: classification, preparation, and applications. Nanoscale Res. Lett. 2013; 8: 102.

10. V. P. Torchilin. Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release. 2001; 73: 137–172.

11. D. Peer et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007; 2: 751–760.

12. Y. H. Bae and K. Park. Targeted drug delivery to tumors: myths, reality and possibility. J. Control. Release. 2011; 153: 198–205.

13. J. Shi et al. Nanotechnology in drug delivery and tissue engineering. J. Exp. Clin. Cancer Res. 2020; 39: 1–23.

14. H. Müller et al. Top-down and bottom-up engineered nanoparticles for drug delivery. Small. 2010; 6(20): 2336–2345.

15. R. H. Müller and K. Peters. Nanosuspensions for poorly soluble drugs. Adv. Drug Deliv. Rev. 2001; 47: 3–19.

16. M. R. J. Barocas et al. Supercritical fluid technology in pharmaceutical science. J. Supercrit. Fluids. 2018; 134: 40–52.

17. F. Alexis et al. Nanotechnology and future drug delivery. Curr. Opin. Pharmacol. 2008; 8: 339–345.

18. O. C. Farokhzad and R. Langer. Impact of nanotechnology on drug delivery. ACS Nano. 2009; 3: 16–20.

19. M. S. Islam and M. Rahman. Nanosuspension technology: recent progress in drug delivery. APS PharmSciTech. 2020; 21: 299–312.

20. X. Zhu et al. Nanotechnology in the diagnosis and treatment of coronary artery disease: recent progress and future perspectives. Adv. Drug Deliv. Rev. 2022; 182: 114097.

21. M. Li et al. Nanomaterial-based biosensors for cardiovascular biomarker detection. Biosens. Bioelectron. 2021; 171: 112687.

22. B. S. Wong et al. Nanoparticle-enhanced imaging for atherosclerosis. Nat. Rev. Cardiol. 2020; 17: 593–604.

23. J. Zhang et al. Biomimetic and natural nanoparticles for targeted cardiovascular therapy. ACS Nano. 2021; 15(2): 3119–3137.

24. J. J. Chong et al. Theranostic nanoplatforms for coronary artery disease. J. Control. Release. 2023; 355: 90–108.

25. R. Wilson and A. P. F. Turner. Glucose oxidase: an ideal enzyme. Biosens. Bioelectron. 1992; 7(3): 165–185.

26. R. Zhang and W. Xu. Nanotechnology in glucose monitoring: a review. Anal. Chim. Acta. 2014; 806: 1–12.

27. J. C. Pickup and F. Hussain. Nanomedicine and its potential in diabetes research and practice. Diabetes Metab. Res. Rev. 2015; 31(6): 604–610.

28. O. Veiseh, B. C. Tang, K. A. Whitehead, D. G. Anderson, and R. Langer. Managing diabetes with nanomedicine: challenges and opportunities. Nat. Rev. Drug Discov. 2015; 14: 45–57.

29. Z. Gu et al. Glucose-responsive micro/nanosystems for closed-loop insulin delivery. ACS Nano. 2013; 7(8): 6758–6766.

30. M. Montazer and T. Harifi, Nanotechnology in Textiles: Advances and Developments. Cambridge: Woodhead Publishing, 2018.

31. T. Shah, R. V. Adivarekar, and A. N. Desai. Application of nanotechnology in textiles. J. Text. Eng. Fashion Technol. 2015; 1(1): 1–7.

32. X. Wang and T. Lin. Nanotechnology for the textile industry: a review. J. Text. Inst. 2008; 99(2): 1–7.

33. H. M. C. De Azeredo. Nanocomposites for food packaging applications. Food Res. Int. 2009; 42(9): 1240–1253.

34. I. Holme. Innovative textile treatments using nanotechnology. Coloration Technol. 2007; 123(2): 59–73.

35. P. Jain, X. Huang, I. El-Sayed, and M. El-Sayed. Review of some interesting surface plasmon resonance-enhanced properties of noble metal nanoparticles. Chem. Phys. Lett. 2010; 487(4–6): 153–164.

36. M. De, P. S. Ghosh, and V. M. Rotello. Applications of nanoparticles in biology. Adv. Mater. 2008; 20(22): 4225–4241.

37. S. M. Moghimi, A. C. Hunter, and J. C. Murray. Nanomedicine: current status and future prospects. FASEB J. 2005; 19(3): 311–330.

38. K. S. Novoselov et al. A roadmap for grapheme. Nature. 2012; 490(7419): 192–200.

39. S. Iijima. Helical microtubules of graphitic carbon. Nature. 1991; 354: 56–58.

40. Foundational paper introducing carbon nanotubes — already covered by 39.

41. R. S. Varadan, L. Chen, and J. Xie, Nanomedicine: Design and Applications of Magnetic Nanomaterials, Nanosensors and Nanosystems. Hoboken, NJ: Wiley, 2008.

42. L. Zhang, F. Gu, and J. Chan. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 2008; 83(5): 761–769.

43. S. Bansal, M. Bansal, and R. Kumria. Nanocrystals: current strategies and trends. Int. J. Res. Pharm. Biomed. Sci. 2012; 3(1); 406–419.

44. D. Rasanta. Nanotechnology for the delivery of poorly water-soluble drugs. Global J. Pharm. Res. 2012; 1(3): 225–250.

45. M. Patel. Nanosuspension: a novel approach for drug delivery system. JPSBR. 2011; 1: 1–10.

46. G. V. Yadav.Nanosuspension: a promising drug delivery system. Pharmacophore. 2012; 3(5): 217–243.

47. A. Malik, S. Chaudhary, G. Garg, and A. Tomar. Dendrimers: a tool for drug delivery. Adv. Biol. Res. 2012; 6(4): 165–169.

48. P. Heera and S. Shanmugam. Nanoparticle characterization and application: an overview. Int. J. Curr. Microbiol. Appl. Sci. 2015; 4(8): 379–386.

49. S. M. Shahidulla, R. Miskan, and S. Sultana. Nanosuspensions in Pharmaceutical Sciences: A Comprehensive Review. International Journal of Health Sciences and Research. 2023; 13(7): 332-342 DOI: 10.52403/ijhsr.20230745.

50. Y. Mengesha. Nanotechnology-Enhanced Controlled-Release Systems in Topical Therapeutics. Precision Nanomedicine. 2024; 7(1): 1365-1385.

51. A. Di Stefano.Nanotechnology in Targeted Drug Delivery. International Journal of Molecular Sciences. 2023; 24(9): 8194 DOI: 10.3390/ijms24098194.

52. J. K. Patra et al. Recent developments and future prospects. Journal of Nanobiotechnology. 2018; 16(71). DOI: 10.1186/s12951-018-0392-8.

53. B. K. Yvon. The impact of nanoscience and nanotechnology on controlled drug delivery. Future Medicine: Nanomedicine. 2014; 9(4): 401 DOI: 10.2217/nnm.14.4.

54. H. B. Omietimi, S. A. Afolalu, J. F. Kayode, S. L. Monye, and S. Lawal. An overview of nanotechnology and its application. E3S Web of Conferences. 2023; 391: 01079. DOI: 10.1051/e3sconf/202339101079.

55. M. Rangasamy. Nano Technology: A Review. Journal of Applied Pharmaceutical Science. 2011; 1(20: 8-16.

56. S. R. H. Alhlimidi, S. H. K. Thillah A. Khadhum Al-musawi. Principles of Nanotechnology (Article review). International Journal of Multidisciplinary Research and Development. 2023; 10(7): 74-76.

57. C.-M. Gavrilescu, C. Paraschiv, P. Horjinec, D.-M. Sotrop, and R. M. Barbu. The advantages and disadvantages of nanotechnology. Romanian Journal of Oral Rehabilitation. 2018; 10(2): 153-157.

58. Rónavári et al. Study of the parameters influencing the co-grinding process for the production of meloxicam nanoparticles. Powder Technology.

59. L. Marinelli et al. Preparation, Characterization, and Biological Evaluation of a Hydrophilic Peptide Loaded on PEG-PLGA Nanoparticles. Pharmaceutics. 2022; 14(9): 1821 DOI: 10.3390/pharmaceutics14091821.

60. B. K. R. Cacciatore et al. Multiple lipid nanoparticles as antimicrobial drug delivery systems. J. Drug Deliv. Sci. Technol. 2022; 67: 102887. DOI: 10.1016/j.jddst.2021.102887.

Received on 16.12.2025 Revised on 14.01.2026

Accepted on 07.02.2026 Published on 21.04.2026

Available online from April 24, 2026

Res. J. Pharma. Dosage Forms and Tech.2026; 18(2):163-171.

DOI: 10.52711/0975-4377.2026.00025

This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License.